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Abstract
Background: Transcription of HIV-1 genes is activated by HIV-1 Tat protein, which induces
phosphorylation of RNA polymerase II (RNAPII) C-terminal domain (CTD) by CDK9/cyclin T1.
Earlier we showed that CDK2/cyclin E phosphorylates HIV-1 Tat in vitro. We also showed that
CDK2 induces HIV-1 transcription in vitro and that inhibition of CDK2 expression by RNA
interference inhibits HIV-1 transcription and viral replication in cultured cells. In the present study,
we analyzed whether Tat is phosphorylated in cultured cells by CDK2 and whether Tat
phosphorylation has a regulatory effect on HIV-1 transcription.
Results: We analyzed HIV-1 Tat phosphorylation by CDK2 in vitro and identified Ser16 and Ser46
residues of Tat as potential phosphorylation sites. Tat was phosphorylated in HeLa cells infected
with Tat-expressing adenovirus and metabolically labeled with 32P. CDK2-specific siRNA reduced
the amount and the activity of cellular CDK2 and significantly decreased phosphorylation of Tat.
Tat co-migrated with CDK2 on glycerol gradient and co-immunoprecipitated with CDK2 from the
cellular extracts. Tat was phosphorylated on serine residues in vivo, and mutations of Ser16 and Ser46
residues of Tat reduced Tat phosphorylation in vivo. Mutation of Ser16 and Ser46 residues of Tat
reduced HIV-1 transcription in transiently transfected cells. The mutations of Tat also inhibited
HIV-1 viral replication and Tat phosphorylation in the context of the integrated HIV-1 provirus.
Analysis of physiological importance of the S16QP(K/R)19 and S46YGR49 sequences of Tat showed
that Ser16 and Ser46 and R49 residues are highly conserved whereas mutation of the (K/R)19 residue
correlated with non-progression of HIV-1 disease.
Conclusion:  Our results indicate for the first time that Tat is phosphorylated in vivo; Tat
phosphorylation is likely to be mediated by CDK2; and phosphorylation of Tat is important for
HIV-1 transcription.
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Background
The human immunodeficiency virus type 1 (HIV-1)
requires host cell factors for all steps of the viral replica-
tion [1,2]. Recently, multiple covalent modifications of
viral proteins that regulate virus-host protein interactions
have been described, such as phosphorylation, acetylation
and ubiquitination. Phosphorylation has been reported
for almost all HIV-1 accessory proteins, including Vpu [3],
Vpr [4], Vif [5], Nef [6], and Rev [7]. Transcription of HIV-
1 viral genes is induced by a viral transactivator protein
(Tat) [1,2]. The activation domain of Tat (amino acids 1–
48) interacts with host cell factors, whereas the positively
charged RNA-binding domain (amino acids 49–57) inter-
acts with HIV-1 transactivation response (TAR) RNA [1,2].
In cell-free transcription assays Tat induces exclusively
elongation of transcription [8,9]. In vivo, Tat additionally
induces initiation of transcription from the integrated
HIV-1 promoter [10-12]. Tat stimulates formation of tran-
scription complex containing TATA-box-binding protein
(TBP) but not TBP-associated factors (TAFs), thus indicat-
ing that Tat may enhance initiation of transcription [10],
apparently in agreement with the earlier observation that
Tat binds directly to the TBP-containing basal transcrip-
tion factor TFIID [13]. Tat activates HIV-1 transcription by
recruiting transcriptional co-activators that include Posi-
tive Transcription Elongation Factor b (P-TEFb), contain-
ing CDK9/cyclin T1; an RNA polymerase II C-terminal
domain kinase [9,14,15] and histone acetyl transferases
[16-18]. Whereas P-TEFb induces HIV-1 transcription
from non-integrated HIV-1 template [9,14,15], histone
acetyl transferases allow induction of integrated HIV-1
provirus [16-18]. Additional CTD kinases, including
CDK2 and CDK7 were also reported to be activated by Tat
and to induce functional CTD phosphorylation [19,20].
Tat itself is a subject for covalent modifications by host
cell proteins. Tat is directly acetylated at lysine 28, within
the activation domain, and lysine 50, in the TAR RNA
binding domain [21]. Tat is also ubiquitinated at lysine 71
and its ubiquitination stimulates the transcriptional prop-
erties of Tat [22]. Recently, Tat was shown to be methyl-
ated by the arginine methyltransferase, PRMT6 and the
arginine methylation of Tat negatively regulated its tran-
scriptional activity [23]. Surprisingly, in spite of the inter-
action of Tat with P-TEFb and probably other kinases and
its involvement in multiple protein phosphorylation reac-
tions, the phosphorylation of HIV-1 Tat has only been
reported in vitro [24], but not in vivo [25]. HIV-2 Tat was
reported to be phosphorylated in vivo presumably by
CDK9, but this phosphorylation was not important for
Tat-2 function as a transcriptional activator [26]. We pre-
viously reported that Tat dynamically interacts with
CDK2/cyclin E and is also phosphorylated by CDK2/cyc-
lin E in vitro [20]. This dynamic interaction greatly stimu-
lated the activity of CDK2/cyclin E toward
phosphorylation of CTD in vitro [20]. In the present study
we investigated whether Tat is phosphorylated in vivo and
whether this phosphorylation has a regulatory role in Tat-
activated HIV-1 transcription.
Results
Tat is phosphorylated by CDK2 in vitro and Ser-16 and 
Ser-46 residues of Tat are potential phosphorylation sites
We previously showed that Tat is phosphorylated by
recombinant CDK2/cyclin E in vitro and that Tat's Ser16
was a potential phosphorylation site [20]. Indeed recom-
binant CDK2/cyclin E efficiently phosphorylates Tat (Fig.
1A, lane 1). Tat can also be phosphorylated by HeLa
nuclear extract (Fig. 1A, lane 2). Immunodepletion of
CDK2 from HeLa nuclear extract completely abolished Tat
phosphorylation (Fig. 1A, lane 3) suggesting that under
these conditions Tat was largely phosphorylated by
CDK2. Upon analysis of the sequence of Tat, the (S/
T)0P1K2(K/R)3 consensus motif for serine phosphoryla-
tion by CDK2 [27,28] was not found, but several
sequences were found that partially matched this motif:
S16QP(K/R)19 , S46YGR49 , S68LSK71 . To determine poten-
tial phosphorylation sites, Tat phosphorylated in vitro was
analyzed by Mass spectrometry. For this purpose, purified
recombinant Tat was phosphorylated with recombinant
CDK2/cyclin E in vitro followed by immunoprecipitation,
SDS-PAGE purification, in-gel digestion with trypsin, and
HPLC purification. Analysis of HPLC eluates showed pres-
ence of two peaks in the digest generated from phosphor-
ylated Tat that were absent in digest of non-
phosphorylated Tat (Fig. 1B). These two peaks were col-
lected and subjected to MALDI-TOF mass spectrometry.
Masses of the peptides over 900 Da were acquired and
analyzed with FindPep tool [29] using the sequence of Tat
(MEPVDPNLEPWKHPGSQPRTACNNCYCKKCCFHCYA
CFTRKGLGISYGRKKRRQRRRAPQDSQTHQASLSKQ) as
input. The masses of peptides that did not match to Tat
were further compared with Tat peptides from which we
subtracted 18 Da, assuming β-elimination of phosphoric
acid which is likely to occur during MALDI-TOF analysis
[30]. Matched peptides shown in Table 1, indicate that
Peak I contains peptides with Serine 46 as a potential
phosphorylation site, whereas Peak II contains peptides
with Serine 16 as a potential phosphorylation site. All
matched peptides contain internal lysine or arginine resi-
dues, and thus they are apparently products of incomplete
digestion by trypsin, which could be a result of incom-
plete in-gel digestion. Also acquisition of peptide with
masses over 900 Da would only allow detection of rela-
tively large peptides. The data suggest that Tat is phospho-
rylated in vitro by CDK2 and that this phosphorylation
might take place at Ser16 or Ser46 residues within S16QPR19
and S46YGR49 sequences that partially match to the (S/
T)P×(K/R) consensus sequence for CDK2 phosphoryla-
tion [28].Retrovirology 2006, 3:78 http://www.retrovirology.com/content/3/1/78
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Tat is phosphorylated in cultured cells
Previous attempts to detect Tat phosphorylation in vivo
were unsuccessful [25]. We hypothesized that low level of
Tat expression after transfection and/or rapid de-phos-
phorylation by cellular phosphatases might prevent detec-
tion of Tat phosphorylation in vivo. To overcome these
difficulties, we expressed Flag-tagged Tat which we found
to be expressed to a higher level in COS-7 cells than
untagged Tat (Fig. 2, compare lanes 3 and 4). To facilitate
expression of Flag-Tat in HeLa cells we used adenovirus-
mediated expression of Tat [31]. HeLa cells were infected
with Adeno-Tat and incubated 48 hours post infection to
allow expression of Tat. Then cells were pulsed with (32P)-
labeled orthophosphate, and Tat was immunoprecipi-
tated from cellular lysates using monoclonal anti-Flag or
polyclonal anti-Tat antibodies. Immunoprecipitated pro-
teins were resolved by SDS-PAGE on 15% Tris-Tricine gel
[32] and transferred to PVDF membrane. The membrane
was probed with monoclonal anti-Tat antibodies (Fig. 3A)
using 3,3'-Diaminobenzidine enhancer system (DABM,
Sigma), and also exposed to a PhosphoImager screen (Fig.
3B). Both antibodies precipitated a well detectable
amount of Tat protein (Fig. 3A, lanes 3, 4, 6 and 7). Under
these experimental conditions, Tat was phosphorylated
(Figs. 3B and 3C, compare lane 3 to lane 1 and lane 6 to
lane 5). Next we treated cells with okadaic acid, an inhib-
itor of PPP-type phosphatases, to prevent rapid dephos-
phorylation of Tat in the cells and during the lysis
procedure. Treatment with okadaic acid did not change
the amount of precipitated Tat (Fig. 3A, lanes 3, 4, 6 and
7). In contrast, Tat phosphorylation was significantly
enhanced when cells were treated with okadaic acid
(Figs.3B and 3C, lanes 4 and 7). Taken together, these
results indicate that Tat is phosphorylated in vivo and that
Tat phosphorylation is enhanced when cells are treated
with the inhibitor of PPP-phosphatases.
CDK2 phosphorylates Tat in cultured cells
We next investigated whether Tat phosphorylation was
mediated by CDK2 in vivo using CDK2-directed RNA
interference [33]. HeLa cells were infected with Adeno-Tat
and subsequently transfected with siRNAs against CDK2.
Transfection of HeLa cells with siRNAs against CDK2
decreased the level of expression of CDK2 by 2.5-fold
(Figs. 4A and 4B, lane 3). A control non-targeting siRNA
pool did not affect expression of CDK2 (Figs. 4A and 4B,
lane 2). The non-targeting siRNA control was used to
ensure that transfection itself did not affect CDK2 expres-
sion. Western blot analysis of tubulin and CDK9 was used
as control for the specificity of siRNAs. As shown in Fig.
4A transfection with both siRNAs did not affect the level
of  α-tubulin expression. To ensure that CDK2-directed
siRNA decreased the enzymatic activity of cellular CDK2,
CDK2 was immunoprecipitated from cells transfected
with non-targeting or CDK2-directed siRNA and assayed
for its enzymatic activity using recombinant Tat as a sub-
strate. The activity of CDK2 was decreased in the cells
transfected with CDK2-directed siRNA (Fig. 4C, lane 2) as
compared to the cells transfected with non-targeting
siRNA (Fig. 4C, lane 1). Next the cells were infected with
Adeno-Tat, transfected with non-targeting or CDK2-
directed siRNAs and pulse-labeled with (32P). In this
experiment no okadaic acid was used. Inhibition of CDK2
by siRNA reduced the level of Tat phosphorylation by 3-
fold (Figs. 5A,B and 5C, compare lanes 2 and 3). Thus
CDK2 is likely to mediate Tat phosphorylation in cultured
cells. To analyze whether Tat and CDK2 might be present
in the same molecular weight complex, we analyzed sedi-
mentation of Tat and CDK2 by ultracentrifugation on a
glycerol gradient (Fig. 6). Both Tat and CDK2 co-migrated
in fractions 1–8 (Fig. 6). The CDK9 was present in most of
the fractions with the peak in fractions 4–5 and 9–10 (Fig.
6), which is likely to correspond to low and high molecu-
Table 1: Determination of sites of phosphorylation in Tat
Peak Peptides matching to Tat MW -18Da Matching peptides
I (T)RKGLGISYG(R) 950.606 932.606 932.606
931.553
(L)GISYGRKKRR/(Q) 1220.7 1202.7 1202.7
1202.698
(S)YGRKKRRQRR/(R) 1403.779 1385.779 1385.779
1385.777
II (L)EPWKHPGSQPRTACNNCYCK/(K) 2319.272 2301.272 2301.272
2301.274
(P)WKHPGSQPRTAC(N) 1367.563 1349.563 1349.563
1349.544
1349.563
1349.544
(P)WKHPGSQPRTACNN(C) 1595.811 1577.811 1577.811,
1576.779
(P)NLEPWKHPG(S) 1077.606 1059.606 1059.606Retrovirology 2006, 3:78 http://www.retrovirology.com/content/3/1/78
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Analysis of HIV-1 Tat phosphorylated by CDK2/cyclin E in vitro Figure 1
Analysis of HIV-1 Tat phosphorylated by CDK2/cyclin E in vitro. A, Tat is phosphorylated by CDK2. Recombinant 
Tat was phosphorylated in vitro by purified CDK2/cyclin E (lane 1), by HeLa nuclear extract (lane 2) or by CDK2-depleted 
HeLa nuclear extract (lane 3). Tat was resolved by 12% SDS Tris-Tricin PAGE. The gel was stained with Coomassie blue 
(upper panel) and exposed to Phospho Imager screen (lower panel). B, HPLC profiles of Tat peptides after trypsin 
cleavage. Recombinant Tat was phosphorylated in vitro by purified CDK2/cyclin E, resolved by 12% SDS Tris-Tricin PAGE, and 
subjected to in-gel trypsin digestion. The eluted peptides were resolved by reverse phase chromatography on μRPC C2/C18 
ST 4.6/100 column. No Tat, mock trypsin digest without Tat. Tat, digest of non-phosphorylated Tat. (Phospho)-Tat, digestion of 
phosphorylated Tat. I and II, peaks identified in the elution profile of phosphorylated Tat that were subjected to MALDI TOF/
TOF mass spectrometry.
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Expression of untagged and Flag-tagged Tat Figure 2
Expression of untagged and Flag-tagged Tat. COS-7 cells were transfected with Tat (lane 3) and Flag-tagged Tat (lane 4) 
expression vectors or mock-transfected (lane 2). At 48 hours post transfection cells were lysed and Tat was immediately 
immunoprecipitated with anti-Tat rabbit polyclonal antibodies (lanes 2–4). Immunoprecipitated Tat was resolved by 15% Tris-
Tricine SDS-PAGE, transferred to polyvinylidene fluoride membrane and immunoblotted with anti-Tat monoclonal antibodies 
using the 3,3'-diaminobenzidine enhancer system. Positions of Tat and Flag-Tat are indicated. Lane 1, prestained 10 kDa molec-
ular weight markers.
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HIV-1 Tat is phosphorylated in cultured cells Figure 3
HIV-1 Tat is phosphorylated in cultured cells. HeLa cells were infected with recombinant adenovirus expressing Flag-
tagged Tat as described in Methods (lanes 3, 4, 6 and 7). Lanes 1, 2, and 5 – control uninfected cells. At 48 hours post infection 
cells were labeled with (32P)-orthophosphate for 2 hours without (lanes 1, 3 and 6) or with (lanes 2, 4, 5 and 7) 1 μM okadaic 
acid (OA). Whole cell extracts were prepared and Tat was immunoprecipitated with anti-Tat rabbit polyclonal antibodies 
(lanes 1–4) or anti-Flag monoclonal murine antibodies (lanes 5–7). Immunoprecipitated Tat was resolved by 15% Tris-Tricine 
SDS-PAGE, and transferred to polyvinylidene fluoride membrane. A, immunoblot of the membrane with anti-Tat monoclonal 
antibodies using the 3,3'-diaminobenzidine enhancer system. B, autoradiography of the membrane on Phosphor Imager. C, 
quantification of panel B. The position of light chain of IgG recognized in anti-Flag immunoprecipitates by anti-mouse HRP-con-
jugated secondary antibodies is indicated by asterisk.
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lar weight P-TEFb complexes. HEXIM1, and Brd4 were
mostly present in fractions 2–6, although HEXIM1 was
also detected in higher molecular weight fractions 10 and
11 (Fig. 6). Neither Tat nor CDK2 co-migrated with
RNAPII which was present in fractions 1–13 (Fig. 6). We
further analyzed association of Tat with CDK2 by immu-
noprecipitation. Flag-Tat was expressed in HeLa cells by
infection with Adeno-Tat and precipitated from cellular
extracts with anti-Flag antibodies (Fig. 7A). CDK2 co-pre-
cipitated with Tat (Fig. 7A, lane 4). CDK2 was not precip-
itated with anti-Tat antiserum from non-infected cells
(Fig. 7A, lane 3) or not with non-specific preimmune
serum from adeno-Tat infected cells (Fig. 7A, lane 5).
Inhibition of CDK2 expression by CDK2-specific RNAi
significantly reduced CDK2 co-precipitated to Tat appar-
ently due reduction of the expressed CDK2 (Fig. 7B, com-
pare lane 4 to lane 2). Association of Tat with CDK9 was
slightly reduced (Fig. 6B) but this reduction correlated to
the decreased amount of Tat precipitated by anti-Flag anti-
bodies. Binding of Tat-cyclin T1 was not reduced (Fig. 7C,
lanes 3 and 5). The cyclin T2 did not precipitate with Tat
(Fig. 7C), which indicated a specificity of the immunopre-
cipitation. Taking together, these results suggest that
CDK2 associates with Tat in cultured cells, and that inhi-
bition of CDK2 expression prevents Tat phosphorylation.
Thus, CDK2 is likely to phosphorylate Tat directly in cul-
tured cells.
Tat is phosphorylated on serine residues in vivo
We next determined whether serine, threonine or tyrosine
residues of Tat were phosphorylated in vivo. HeLa cells
were infected with Adeno-Tat, labeled with (32P), and
treated with okadaic acid to achieve a higher level of Tat
phosphorylation. Tat was immunoprecipitated with anti-
Flag antibody and resolved on 15% SDS Tris-Tricine PAGE
(Fig. 8A, lane 1). Phosphoamino acid analysis of radioac-
tive Tat extracted from the gel (see Materials and Methods)
showed presence of phospho-serines but not phospho-
threonines or phospho-tyrosines in (32P)-labeled Tat (Fig.
8B). Thus, only serine residues of Tat were phosphor-
ylated in vivo.
Phosphorylation of S16 and S46 residues of Tat in vivo
We next investigated a possibility that Tat might be phos-
phorylated on S16 or S46 residues in vivo. We generated
mutants of Flag-Tat in which either or both Ser residues
were substituted by Ala. 293T cells were transfected with
WT and mutant Tat-expressing vectors, Tat was precipi-
tated with anti-Flag antibodies and analyzed on 15% SDS
Tris-Tricine PAGE followed by PhosphoImager analysis.
Expression of Tat was verified by Western blotting (Fig.
8C). While we could detect phosphorylation of WT Tat
(Fig. 8C, lane 2), the Tat S16A mutant and Tat S46A
mutant were about 2–3 fold less phosphorylated (Fig. 8C,
middle and lower panels, lanes 3 and 4). The Tat S16,46A
double mutant was even less phosphorylated (Fig. 8C,
lane 5). Our results indicate that both S16 and S46 are likely
to be phosphorylated in vivo.
Contribution of S16 and S46 residues of Tat to HIV-1 
transcription
We next investigated the functional relevance of Tat's S16
and S46 residues in HIV-1 transcription. We generated
mutants of Tat in which either or both Ser residues were
substituted by Ala. To ensure expression of the mutants,
COS-7 cells were transfected with WT and mutant Tat-
expressing vectors and cellular lysates were analyzed on
15% SDS Tris-Tricine PAGE followed by Western blot
with anti-Tat antibodies. As shown in Fig. 9A, all Tat
mutants were expressed, with the level of expression of Tat
mutants higher than the WT Tat. The higher expression
level of non-tagged Tat mutants was a reproducible effect
and was not a consequence of the difference in the
amount of transfected DNA. The effect of Tat mutations
on the ability of Tat to activate HIV-1 LTR promoter was
analyzed in HeLa cells co-transfected with Tat-expression
vectors and HIV-1 LTR-LacZ reporter plasmid (Fig. 9B).
Non-mutated Tat (WT) increased the level of transcription
by 400-fold (Fig 9B). HIV-1 transcription induction by the
Tat S16A mutant was approximately 75% that of WT Tat
(Fig. 9B), while transactivation by the Tat S46A mutant
was about 2 times lower than with the WT Tat (Fig. 9B)
and induction by the double S16, 46A Tat mutant was 3-
times lower than that of WT Tat (Fig. 9B). Thus, mutation
of either Ser16 or Ser46 of Tat interferes with the level of
Tat-transactivation and mutation of both residues has an
additive effect.
Contribution of S16 and S46 residues of Tat to the HIV-1 
viral production and Tat phosphorylation in the context of 
the integrated HIV-1 provirus
We determined whether mutations of Tat S16A and/or
S46A have an effect on the ability of Tat to induce HIV-1
transcription from an integrated HIV-1 provirus. We used
HLM-1 cells (AIDS Research and Reference Reagent Pro-
gram) that were derived from HeLa-CD4+ cells containing
an integrated copy of HIV-1 proviral genome with a Tat-
defective mutation (termination linker at the first AUG).
HLM-1 cells are negative for virus particle production, but
can be induced to express high levels of infectious HIV-1
after transfection with Tat. We transfected the HLM-1 cells
with wild type or mutant Tat vectors and tested superna-
tants for the presence of HIV-1 particles using p24 gag
antigen ELISA at day 0, day 1, day 2, day 7 and day 14
posttransfection. Neither S16A nor S46A mutants of Tat
efficiently induced HIV-1 viral production (Fig. 10A). The
double S16, 46A mutant also had a reduced activity (Fig.
10A). To phosphorylate Tat during virus replication, we
pulsed HLM-1 cells transfected with WT and mutant Tat
with (32P) orthophosphate and also treated the cells withRetrovirology 2006, 3:78 http://www.retrovirology.com/content/3/1/78
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CDK2-directed siRNA inhibits CDK2 expression Figure 4
CDK2-directed siRNA inhibits CDK2 expression. A, CDK2-directed siRNA inhibits expression of CDK2. HeLa cells 
were transfected with siRNAs targeting CDK2 (lane 3) or non-targeting control pool (control, lane 2). Lane 1, untransfected 
cells. At 48 hours post-transfection cells were lysed and cellular extracts were resolved on 12% Tris-Tricine SDS-PAGE and 
analyzed by immunoblotting analysis with antibodies against CDK2, CDK9 or α-tubulin. B, quantification of the CDK2 expres-
sion in panel A using α-tubulin expression level for normalization. C, CDK2-directed siRNA inhibits enzymatic activity of 
CDK2. CDK2 was precipitated from cellular extracts prepared from HeLa cells transfected with siRNAs targeting CDK2 (lane 
2) or non-targeting control (lanes 1 and 3). Lanes 1 and 2, precipitation with rabbit anti-CDK2 antibodies. Lane 3, precipitation 
with rabbit preimmune serum. Immunoprecipitates were incubated with γ-(32P)ATP and recombinant Tat (see Methods), 
resolved on 12% Tris-Tricine SDS-PAGE and analyzed by autoradiography on Phosphor Imager. Position of Tat is indicated.
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CDK2-directed siRNA blocks Tat phosphorylation Figure 5
CDK2-directed siRNA blocks Tat phosphorylation. A, HeLa cells were infected with Adeno-Tat (lanes 2 and 3). At 4 
hours post infection, cells were transfected with siRNAs targeting CDK2 (lane 3) or non-targeting control pool (lane 2). Lane 
1 – control cells. At 48 hours post-infection cells were labeled with (32P)-orthophosphate for 2 hours. Whole cell extract was 
subjected to immunoprecipitation with anti-Flag antibodies, resolved by 15% Tris-Tricine SDS-PAGE, and transferred to polyvi-
nylidene fluoride membrane. A, immunoblot of the membrane with anti-Tat monoclonal antibodies using the 3,3'-diaminobenzi-
dine enhancer system. B, autoradiography of the membrane on Phosphor Imager screen. C, quantification of the panel B. 
Position of Tat is indicated by arrow. The position of light chain of IgG recognized in anti-Flag immunoprecipitates by anti-
mouse HRP-conjugated secondary antibodies is indicated by asterisk.
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okadaic acid. Tat was immunoprecipitated with anti-Flag
antibodies, resolved on 15% SDS PAGE and its phospho-
rylation was detected by PhosphoImager. While WT Tat
was phosphorylated, the mutants were not phosphor-
ylated efficiently (Fig. 10B). These data indicate that the
S16A and S46A mutations of Tat interfere with the ability
of Tat to activate integrated HIV-1 provirus, and prevent
Tat phosphorylation during one round of viral replica-
tion.
Correlation of mutations in putative CDK2 recognition 
sites on Tat with disease progression in HIV infected 
humans
As we discussed above, analysis of the sequence of Tat for
the presence of the (S/T)0P1K2(K/R)3 consensus motif for
serine phosphorylation by CDK2 [27,28] showed that
several sequences partially matched this motif: 16SQP(K/
R)19 , 46 SYGR49 , 68SLSK71 . We determined conservancy of
S16, S46 and S68 residues. We analyzed 158 sequences of
Tat and CDK2 co-migrate on glycerol gradient Figure 6
Tat and CDK2 co-migrate on glycerol gradient. 293T cell lysated from the cells infected with Adeno-Tat were fraction-
ated on 10%–30% glycerol gradients by centrifugation and analyzed with indicated antibodies by Immunoblotting.
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A, CDK2 associates with Tat in cultured cells Figure 7
A, CDK2 associates with Tat in cultured cells. Flag-tagged Tat was expressed in HeLa cells by Adeno-Tat infection and 
precipitated with anti-Flag antibodies from cellular lysate. Co-precipitated proteins were resolved on 12% Tris-Tricine PAGE 
and analyzed by immunoblotting analysis with anti-CDK2 and anti-Tat antibodies. Lane 1, input control without Tat. Lane 2, 
input control with Tat. Lanes 3 and 4, extract without or with Tat precipitated with anti-Flag antibodies. Lane 5, extract with 
Tat precipitated with preimmune mouse IgG. The position of light chain of IgG recognized in anti-Flag immunoprecipitates by 
anti-mouse HRP-conjugated secondary antibodies is indicated by asterisk. B, CDK2-specific siRNA inhibits association of 
Tat with CDK2. Flag-tagged Tat was expressed in 293T cells by transfection (lanes 2 and 4). Cells were transfected with non-
targeting (lanes 1 and 2) or CDK2-specific (lanes 3 and 4) siRNAs. Lysates were precipitated with anti-Flag antibodies, resolved 
on 12% Tris-Tricine PAGE and immunoblotted with anti-Tat, anti-CDK9 or anti-CDK2 antibodies. C, CDK2-specific siRNA 
does not affect association of Tat with cyclin T1. Flag-tagged Tat was expressed in 293T cells by transfection (lanes 3 
and 5). Cells were transfected with non-targeting (lanes 2 and 3) or CDK2-specific (lanes 4 and 5) siRNAs. Lysates were pre-
cipitated with anti-Flag antibodies, resolved on 12% Tris-Tricine PAGE and immunoblotted with anti-Tat, anti-CDK9 or anti-
CDK2 antibodies. Lane 1, input.
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HIV-1 Tat is phosphorylated on S16 and S46 residues in vivo Figure 8
HIV-1 Tat is phosphorylated on S16 and S46 residues in vivo. A, HeLa cells were infected with recombinant adenovirus 
expressing Flag-tagged Tat as described in Methods. At 48 hours post infection cells were labeled with (32P)-orthophosphate for 
2 hours with 1 μM okadaic acid (OA). Lane1, Flag-Tat was immunoprecipitated from whole cell extracts with anti-Flag antibod-
ies and resolved by 15% Tris-Tricine SDS-PAGE. Lane 2, control mock-transfected cells. The picture is an autoradiogram. B, 
Tat peptides were eluted from the gel shown in panel A by overnight incubation with trypsin and subjected to acid hydrolysis 
as described in Materials and Methods. The hydrolyzed material was spotted on nitrocellulose plate and examined by two-
dimensional thin layer electrophoresis and autoradiography. The indicated positions of non-radioactive phospho-amino acid 
standards were visualized by staining with 0.5% ninhydrin in ethanol. C, Mutations of S16 and S46 reduce Tat phosphorylation in 
vivo. 293T cells were transfected with vectors expressing Flag-tagged WT Tat (lane 2), Tat S16A (lane 3), Tat S46A (lane 4) or 
Tat S16,46A (lane 5). Lane 1, mock transfection. At 48 hours post-transfection the cells were labeled with (32P)-orthophos-
phate for 2 hours. Whole cell extract was subjected for immunoprecipitation with anti-Flag antibodies, resolved by 15% Tris-
Tricine SDS-PAGE, and analyzed by Western blotting with polyclonal anti-Tat antibodies and on Phosphor Imager. Quantifica-
tion is shown in the lower panel. Position of Tat is indicated by arrow.
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Tat isolates deposited in the PubMed database. Both S16
and S46 were highly conserved with an occurrence of
100% or nearly 100% (Fig. 11). In contrast, S68  was
present in 41%, and S70 – in 60% of the Tat isolates and
all other serines were present in less than 50% (Fig. 11).
This analysis indicates that S16 and S46 residues might be
critical for HIV-1 replication. Because S16 and S46 residues
were 100% conserved, it was not possible to analyze the
effect of the mutation of these residues on the HIV-1 pro-
gression. We took advantage of the notion that a lysine or
arginine present in the fourth position of the (S/
T)0P1K2(K/R)3 consensus motif is critical for the recogni-
tion of the motif by CDK2 [27,28]. Thus we analyzed
whether (K/R)19 and R49 residues within 16SQP(K/R)19
and 46 SYGR49 sequences of Tat were conserved among dif-
ferent HIV-1 isolates and whether mutations in these res-
idues correlated with apparent progression of disease in
the patient from whom the isolates were obtained. In this
investigation, we studied 105 sequences of Tat deposited
to PubMed database [34]. Of these, 55 were obtained
Mutations of Ser16 and Ser46 of Tat reduce its transactivation potential Figure 9
Mutations of Ser16 and Ser46 of Tat reduce its transactivation potential. A, COS-7 cells were transfected with WT 
Tat, Tat S16A, Tat S46A or Tat S16,46A expression vectors. At 48 hours posttransfection, the cells were lysed. Tat was immu-
noprecipitated from the lysates with rabbit polyclonal antibodies, resolved by 15% Tris-Tricine SDS-PAGE and immunoblotted 
with monoclonal anti-Tat antibodies. B, HeLa cells were transfected with the HIV-1 LTR-LacZ expression vector alone (not 
shown here) and in combination with WT Tat, Tat S16A, Tat S46A or Tat S16,46A expression vectors. At 48 hours posttrans-
fection, cells were lysed and analyzed for β-galactosidase activity with ONPG.
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A, Mutations of S16 and S46 of Tat reduce its ability to induce viral production Figure 10
A, Mutations of S16 and S46 of Tat reduce its ability to induce viral production. HLM1 is a HeLa derived cells contain-
ing one copy of integrated HIV-1 proviral genome with a Tat-defective mutation. Various Flag-tagged Tat (WT Tat, Tat S16A, 
Tat S46A or Tat S16,46A) expression vectors were used for HLM-1 transfections. Cells were cultured in complete media in 
absence of G418 for 14 days. The supernatants were collected at Day 0, 1, 2, 7 and 14, and analyzed for p24 by ELISA assay. B, 
Mutations of S16 and S46 of Tat inhibit Tat phosphorylation during one round of viral replication. HLM1 cells were 
transfected with vectors expressing Flag-tagged Tat (WT Tat, Tat S16A, Tat S46A or Tat S16,46A). At 48 hours post transfec-
tion the cells were labeled with (32P)-orthophosphate for 2 hours with 1 μM okadaic acid. Flag-Tat was immunoprecipitated 
from whole cell extracts with anti-Flag antibodies and resolved by 15% Tris-Tricine SDS-PAGE. The gel was dried and exposed 
to Phosphor Imager screen. Lane 1, Wt Tat. Lane 2, Tat S16A. Lane 3, Tat S46A. Lane 4, Tat S16,46A. Lane 5, mock-trans-
fected cells. The picture is an autoradiogram.
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from patients who were not on antiretroviral treatment
and were classified as being healthy, and 50 were from
patients who were classified as being ill and who were on
antiretroviral treatment. We found that R49 was absolutely
conserved, and thus no correlation could be obtained. In
contrast, Table 2 shows that 29 (53%) of the "healthy"
HIV patients had a (K/R)19 mutation compared to only 4
(8%) of the "ill" HIV patients (Pearson Chi-square corre-
lation 24.312, df = 1; P < 0.001). This result suggests phys-
iological importance of mutation of position 19 of Tat for
progression of HIV-1 disease, and are consistent with the
possibility that 16SQP(K/R)19 sequence is a putative CDK2
recognition site in Tat.
Discussion
Our recent studies indicate that Tat's role in HIV-1 tran-
scription is extremely complex and may not confine solely
to the interaction with CDK9/cyclin T1. We have previ-
ously reported that Tat interacts directly or indirectly with
host cell protein phosphatase 1 (PP1) and protein phos-
phatase 2A (PP2A). Tat binds to protein phosphatase-1
(PP1) and this binding is important for the induction of
HIV-1 transcription by Tat [31,35]. Tat interaction with
PP1 is intriguing as PP1 regulates CDK9 phosphorylation
in vivo [36]. We recently showed that Tat binds to LIS1
protein, a product of lissencephaly gene which mutations
cause a severe brain malformation [37]. LIS1 resembles
the B-subunit of PP2A and interacts with the catalytic sub-
unit of PP2A; and LIS1 expression induces HIV-1 tran-
scription [38]. Thus Tat might also be able to interact with
PP2A, although not directly with its catalytic subunit. The
current study adds more complexity to the Tat function
showing that Tat might undergo phosphorylation by
CDK2/cyclin E.
We hypothesized here that CDK2 affects HIV-1 transcrip-
tion by phosphorylating Tat and that Tat phosphorylation
might be important for HIV-1 transcription. We show
here that Tat undergoes phosphorylation in vivo on serine
residues, and that CDK2 is involved in this phosphoryla-
tion. Our findings also indicate that phosphorylation of
Tat is important for HIV-1 transcription and the activation
of integrated HIV-1 provirus. In our previous work we
demonstrated that CDK2/cyclin E phosphorylates the C-
terminal domain of RNA polymerase II in vitro [39-41];
that CDK2 was required for Tat-dependent transcription
in vitro, and that CDK2 phosphorylates HIV-1 Tat in vitro
[20,41]. CYC202 (R-roscovitine), a pharmacological
inhibitor of CDK2, efficiently inhibited replication of
wild type and HAART resistant HIV-1 mutants in T-cells,
monocytes and PBMCs [42] indicating that CDK2 activity
is required for HIV-1 replication. Recently we showed that
siRNA-directed against CDK2 inhibits Tat-induced HIV-1
transcription and HIV-1 viral replication [33]. Thus our
present study as well as our previous studies point to
CDK2 as an important regulator of HIV-1 transcription.
Until recently CDK2/cyclin E was considered to be essen-
tial for cell cycle progression and that CDK2 regulates G1/
S transition by phosphorylating Rb-sequestering factors,
including E2F [43]. Recent findings challenged this role of
CDK2. CDK2 knock-out mice were viable [44], suggesting
that CDK2 is dispensable for proliferation and survival of
most cell types. Also, inhibition of CDK2 activity through
expression of p27 Kip1, dominant-negative CDK2, anti-
sense oligonucleotides or siRNA did not have an effect on
growth of several tumor cell lines [45]. Therefore, not
being essential for cellular viability, CDK2 might present
a feasible target for anti-HIV-1 therapeutics.
Previous attempts to detect Tat phosphorylation in vivo
were not successful [25]. It is possible that low level of Tat
expression or fast dephosphorylation in the cells or dur-
ing sample preparation may not allow easy detection of
Tat phosphorylation. For example, in the early studies Ben
Berkhout and his colleagues could only detect Tat expres-
sion in COS-7 cells but not in HeLa cells [46-48]. We
found that expression of Flag-tagged Tat allowed higher
levels of Tat expression especially with the adeno-virus
mediated delivery. Treatment with okadaic acid, which
inhibits phosphatases of the PPP-family including PP1
and PP2A [49], significantly enhanced Tat phosphoryla-
tion (Fig. 3), suggesting that Tat may be dynamically
dephosphorylated by a cellular PPP-type phosphatase.
When we inhibited PP1 by over expression of the central
domain of nuclear inhibitor of PP1 (NIPP1) [31] we did
not detect changes in Tat phosphorylation (data not
shown). Thus PP2A rather than PP1 is a candidate phos-
phatase to dephosphorylate Tat.
Our analysis showed that inhibition of CDK2 expression
by siRNA substantially blocked Tat phosphorylation and
prevented association of Tat with CDK2. Although these
findings suggest that CDK2 might directly phosphorylate
Tat, we also cannot rule out a possibility that inhibition of
Table 2: Mutation of (K/R)19 residue sequence of Tat and Sickness Status
Healthy Sick  Total
Non-mutated Tat (K/R)19 26 46 72
Tat (K/R)19(T, A or G) 29 4 33
Total 55 50 105Retrovirology 2006, 3:78 http://www.retrovirology.com/content/3/1/78
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CDK2 reduces the activity of another kinase that in turn
might be involved in Tat phosphorylation. Finding that
Tat co-migrates with CDK2 on glycerol gradient and also
co-precipitated with CDK2 confirms our previous obser-
vation that Tat-associated kinase activity contained CDK2
[41]. CDK2-directed siRNA significantly reduced associa-
tion of CDK2 to Tat, probably by reducing the amount of
CDK2 available to interact with Tat.
We found that Tat is phosphorylated on serine residues in
vivo. We previously suggested that the 16SQPK19 and K41 ×
L43 sequences of Tat interact with CDK2 and cyclin E
respectively, and that S16 is phosphorylated by CDK2
[20]. In the present study we found that both S16 and S46
of Tat are potential phosphorylation sites. As S46 is adja-
cent to the K41 × L43 sequence of Tat, it is likely that the K41
× L43 sequence participates in binding to CDK2 rather
than to cyclin E, as we originally suggested. Interestingly,
recombinant CDK2/cyclin E only phosphorylated full
length Tat 1–72 but not the 15 amino acid peptides of Tat,
9EPWKHPGSQPKTACN23  or  37CFTTKGLGISYGRKK51
(AIDS Research and Reference Reagents Program, NIH),
containing only the phosphorylation sites (data not
shown), which may indicate a requirement of additional
sequences of Tat for its interaction with CDK2/cycline E.
Another explanation is that full length Tat creates a favo-
rable conformation for phosphorylation by CDK2. The
sequences  16SQP(K/R)19  and  46SYGR49  only partially
match the CDK2 (S/T)0P1K2(K/R)3  phosphorylation
motif. Although the catalytic efficiency of CDK2-cyclin A
is impaired 2000-fold, when Pro1 is substituted with Ala
in a short synthetic peptide substrate, physiological sub-
strates for both CDK2-cyclin A and CDK2-cyclin E often
contain phosphorylation motifs replaced with sub opti-
mal determinants [28]. In such sub optimal substrates
phosphorylation is enhanced by a cyclin-binding motif
that compensates for otherwise poor catalysis [28]. There-
fore, binding of cyclin E still might be important for effi-
cient phosphorylation of Tat by CDK2.
Using mutation analysis, we found that S16 and S46 are
equally important for activation of integrated proviral
DNA. The single point mutants did not show a significant
level of activation, and the double mutant Tat was com-
pletely inactive in HLM-1 cells. In contrast, mutation of
S16 and S46 moderately reduced activation of HIV-1 tran-
Serine residues at position 16 and 46 are highly conserved in Tat isolates Figure 11
Serine residues at position 16 and 46 are highly conserved in Tat isolates. The 158 sequences of Tat isolates depos-
ited to PubMed database were analyzed for the presence of serines at position 16, 23, 46, 61, 68, 70, 73, 74 and 75. Presence 
of a serine at the indicated position is presented as a percent of the total number of the isolates analyzed.
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scription from the episomal promoter. Thus Tat S16 and
S46  residues are important for transcription of a full
genomic HIV-1 template containing natural chromatin
structure. The effect of alanine mutation of S46 is at vari-
ance with the previously published observation that
alanine mutation of S46 induces Tat-transactivation [50].
We did not see an increase of Tat transactivation with all
mutants tested. Thus we cannot explain this discrepancy.
Tat was proposed to form aggregates in the nucleus [51].
Using yeast two-hybrid system, we found no evidence that
Tat forms dimers in yeast cells (not shown). Therefore, it
remains to be determined why Tat should undergo phos-
phorylation to be fully active as a transcriptional activator.
We did not detect a difference between WT and mutant
Tat in ability to bind to TAR RNA (not shown). We
observed an increase in the expression of untagged Tat
with mutations in the S16 or Ser46 Tat residues and partic-
ular of the double mutant of Tat (Fig. 8A). An increase in
Tat expression was observed earlier by Rice and Carlotti
with a mutant of Tat that lacked first 36 N-terminal amino
acids [50]. Thus the amount of Tat expressed in the cells
might be stringently controlled and the excess of Tat
might have a negative effect on Tat transactivation.
Another possibility is that Tat may need to undergo non-
proteolytic ubiquitination by Hdm2 ubiquitin ligase [22]
to be fully active as a transactivator. It is possible that Tat
phosphorylation may facilitate ubiquitination of Tat by
Hdm2 similar to phosphorylation-dependent ubiquitina-
tion of p53 by Hdm2 [52].
Analysis of Tat sequences available in the PubMed
showed that Tat isolates contain from 4 to 11 serine resi-
dues. In addition to the highly conserved S16 and S46 resi-
dues, Tat contains less conserved serines at positions 23,
61, 62, 68, 70, 73, 74 and 75. Analysis of the 16SQP(K/
R)19 and  46SYGR49 sequences of Tat, showed that R49 is
conserved among different HIV-1 isolates. Interestingly,
mutations in the (K/R)19 residue showed correlation with
non-progression of HIV-1 disease. Thus (K/R)19 residue
which is part of a putative CDK2 recognition site in Tat,
may be important for progression of HIV-1 disease. Future
study will address whether mutation of (K/R)19 residue is
important for phosphorylation of Tat by CDK2 and
whether mutations in this residue affect viral replication.
Taken together, our findings indicate that Tat is phospho-
rylated in vivo and that phosphorylation of Tat is impor-
tant for the activation of integrated HIV-1 provirus. Our
finding also indicates that CDK2 associates with Tat and
thus is likely to phosphorylate Tat directly in vivo. Our
findings open the door to the evaluation of the potential
efficiency of presently available CDK2 inhibitors and spe-
cifically designed future inhibitors to disrupt CDK2-Tat
association.
Methods
Materials
293T cells and COS-7 cells were purchased from ATCC
(Manassas, VA). HeLa-MAGI cells [53], HLM-1 cells [54],
anti-Tat rabbit polyclonal (HIV-1 BH10 Tat antiserum,
[55]) and monoclonal (NT3 2D1.1, courtesy of Dr.
Jonathan Karn) antibodies were received from the AIDS
Research and Reference Reagents Program (NIH). Anti-
Flag monoclonal antibodies, anti-α-tubulin antibodies,
protein (G) and protein (A) agarose and okadaic acid were
purchased from Sigma (Atlanta, GA). All radioactive rea-
gents were purchased from GE Health Care Life Sciences.
The 3,3'-diaminobenzidine enhanced liquid substrate sys-
tem for membrane ELISA (DABM) was purchased from
Sigma (St Louis, MO). Antibodies for CDK2, CDK9, cyclin
T1 and cyclin T2 were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). Antibodies against RNAPII were
from Babco. Anti-Brd4 and anti-HEXIM1 antibodies were
a gift from Dr.Q. Zhou (University of California, Berke-
ley). HIV-1 Tat was expressed in Escherichia coli and puri-
fied on Aquapore RP-300 column (Applied Biosystems,
Foster City, CA) by reverse-phase chromatography as we
described [20].
Plasmids
Tat expression plasmid was a gift from Dr. Ben Berkhout
(University of Amsterdam) [48]. The Flag-Tat was cloned
into the adeno-CMV-link vector as described below and
verified by sequencing. The S16A and S46A mutations of
the sequence of Tat were made according to the Quick-
Change site-directed mutagenesis protocol of Stratagene,
using the appropriate primers and templates. The
sequences of the DNA constructs were verified by
sequencing using a commercial service from Macrogen
(Seoul, Korea).
CDK2/cyclin E purification
CDK2 and cyclin E were purified from lysates of Sf9 insect
cells infected with baculoviruses producing CDK2 and
cyclin E. Proteins were purified essentially as described
earlier [56]. Briefly, 1 ml of cells (from 250 ml of culture)
was lysed with 16 ml of lysis buffer (50 mM Tris-HCl, pH
8.0, 10 mM 2-mercaptoethanol, 10% glycerol and with
PMSF), homogenized on ice and centrifuged at 45,000 g
for 1 hr at 4°C. Supernatant was loaded on Mono-Q 10/
10 column (Amersham, USA). Two separate cell cultures,
one infected with CDK2-expressing baculovirus and the
other one infected with cyclin E-expressing baculovirus
were used for purification. The Mono-Q fractions contain-
ing CDK2 or cyclin E were mixed 1:1 and loaded onto
Superdex column (Sephadex H200, Amersham, USA).
Purity of CDK2/cyclin E was checked on 12% PAGE fol-
lowed by Coomassie staining (Additional file 1). We also
analyzed the Superdex fractions by immunoblotting with
andti-CDK2 antibodes and assayed their enzymatic activ-Retrovirology 2006, 3:78 http://www.retrovirology.com/content/3/1/78
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ity using histone H1 and purified Tat proteins as sub-
strates. Fractions containing CDK2/cyclin E were
concentrated using Microcon tubes (Amicon, USA).
In vitro kinase assay
CDK2 kinase assays were performed at 30°C for 30 min
in kinase assay buffer (50 mM HEPES-KOH, pH 7.9, 10
mM MgCl2, 6 mM EGTA, 2.5 mM DTT) containing his-
tone H1 or purified Tat protein, 200 μM ATP and (γ-
P32)ATP. A mixture was incubated for 30 min at 30°C,
reaction was stopped with 8 μl of 4× SDS buffer and
resolved on 12% PAGE.
Immunoprecipitation of CDK2 and kinase assay with Tat
293T cells were transfected with CDK2-directed or non-
targeting siRNA. At 48 hours after transfection cells were
lysed in whole cell lysis buffer. About 50 μg of protein
lysate was subjected to precipitation with anti-CDK2 rab-
bit antibodies (600 ng/IP) on 40 μl protein A agarose
beads (50% slurry) (Sigma). As a control, rabbit preim-
mune serum was used. Precipitation was carried out for 2
hrs at 4°C. The beads were washed with TNN buffer, then
with TTK buffer and supplemented with 20 μl of kinase
mixture containing TTK buffer, 100 μM ATP, 0.5 μCi of γ-
(32P)ATP and 1 μg of purified Tat. The kinase reaction was
carried out for 15 min at 30°C, reaction was stopped with
8 μl of 4× SDS-loading buffer and resolved on 12% Tris-
Tricine gel. The gel was stained with Coomassie blue,
dried and exposed to Phosphor Imager screen.
Fractionation of cellular lysates on glycerol gradient
293T cells were infected with Adeno-Tat virus with MOI 1,
and incubated overnight. The cells in 100 mm plate were
lysed with 0.5 ml of whole cell lysis buffer (50 mM Tris-
HCl, pH 7.5, 0.5 M NaCl, 1% NP-40, 0.1% SDS) supple-
mented with protease cocktail (Sigma) and RNasin
(Amersham). Cell lysates were clarified by centrifugation
for 30 min at 10,000 g and loaded on top of 10% to 30%
glycerol (9 ml) gradient. Glycerol gradient buffer con-
tained 20 mM HEPES-KOH, pH 7.9, 150 mM KCl, 200
μM EDTA
The gradient was spun in SW 41Ti rotor (Beckman) at
38,000 rpm for 18 hours. Fractions (0.5 ml) were col-
lected through a needle inserted to the bottom of the tube
and analyzed by Immunoblotting.
Tat trypsinization and chromatographic separation of 
peptides
Non-phosphorylated and phosphorylated Tat were
resolved by 15% Tris-Tricine SDS-PAGE. A gel piece con-
taining Tat was crushed and incubated with 1 μg of por-
cine trypsin (Promega, Madison, WI) in 0.1 M NaHCO3
(pH 7.9) overnight at 37°C. The extracted peptides were
lyophilized, dissolved in 0.1% TCA and separated by
reverse-phase chromatography on a μRPC C2/C18 ST 4.6/
100 column (Amersham Pharmacia Biotech) using AKTA
purifier (AmershamPharmaciaBiotech). Eluent A was
0.1% TCA in water and eluent B was 0.1% TCA in 90%
acetonitrile. The gradient was 5% B for 2 column volumes
(CVs), 5–50% B for 20 CVs, 50–100% B for 12 CVs and
100% B for 4 CVs. The flow rate was 0.5 ml/min.
MALDI-TOF mass spectrometry and peptide sequencing
Fractions from the HPLC separation described above were
lyophilized. Multiple peptide sequences were determined
in a single run by Applied Biosystems Maldi-TOF/TOF
4700 proteomics analyzer (25–30,000 resolution in
reflectron mode, 5 ppm accuracy with IS, subfmole sensi-
tivity for peptide mass fingerprints (PMF), fmole sensitiv-
ity for PSD/CID capacity of >36,000 PMF per 24 hours).
Data were analyzed utilizing a local multi-processor
installation of MASCOT MS PMF and MS/MS PSD, CID
peptide identification software. GPS also supports an inte-
grated MS-MS/MS mode and a chromatographic separa-
tion mode with SEQUEST-like capability.
Preparation of Adeno-Tat
The E1-deleted recombinant Ad carrying Tat was gener-
ated as previously described [31]. Briefly, a cDNA frag-
ment encoding the full length HIV-1 Tat protein was
cloned into the plasmid pCXN was subcloned in the
pAd.CMV link plasmid. The Tat-coding DNA corresponds
to the HIV-1 isolate P9.3 from United Kingdom (Acces-
sion number AF324447). The DNA sequence is ATGGAC-
TACAAGGACGACGA TGACAAAGAA TTCATGGAGC
CAGTAGATCCTAGACTAGAG CCCTGGGAGC ATCCAG-
GAAG TCAGCCTAAG ACTGCTTGTACCCCTTGCTA TTG-
TAAAAAG TGTTGCTTTC ATTGCCAAGT
TTGTTTCACAACAAAAGGCT TAGGCATCTC CTAT-
GGCAGG AAGAAGCGGA GACAGCGACGAA-
GAGCTCCT CAAGACAGTC AGACTCATCA
GGCTTCTCTA TCAAAGCAATCCCTACCCCA AACCCA-
GAGG GACTCGACAG GCCCGGAAGA ATCGAAGAAG-
GAGGTGGAGA GCAAGGCAGAGACAGATCGA
TTCGATTA. It corresponds to the protein sequence of Tat
containing Flag epitope at its N-terminus-
MDYKDDDDKEFMEPVDPRLEPWEHPGSQPKTACTPCY-
CKKCCFHCQVCFTTKGLGISYGRKKRRQRRRAPQD-
SQTHQASLSKQSLPQTQRDSTGPEESKKEVESKAETDRFD
. pAd.CMVlink and Cla I digested adenoviral DNA were
co-transfected into HEK293 cells at a ratio of 3:1 by cal-
cium phosphate precipitation to allow the recombina-
tion. The virus was purified through three rounds of
plaque-purification. Viruses were replicated in HEK293
cells and were purified from a cell lysate by two rounds of
CsCl density gradient centrifugation. The purified virus
was desalted on a Bio-Gel P-6 desalting column (Bio-Rad
Laboratories, Hercules, CA) equilibrated with PBS. The
titer of the virus preparation was determined both byRetrovirology 2006, 3:78 http://www.retrovirology.com/content/3/1/78
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absorbency at 260 nm and by plaque assay. The particle to
plaque forming unit ratio was less than 100. Purified
viruses were suspended in PBS at the desired concentra-
tions.
Tat phosphorylation in vivo
HeLa cells were infected with recombinant Adenovirus
carrying Flag-tagged Tat prepared as we described [31].
The purified virus had a particle to plaque forming unit
(Pfu) ratio of less than 100. We added approximately 10
Pfu per cell to achieve high level of Tat expression in
infected HeLa cells. At 48 hours post infection the media
was changed for 1 hour to a phosphate-free DMEM media
(Life Technologies, Rockville, MD) containing no serum.
Then the media was changed to phosphate-free DMEM
supplemented with 0.5 mCi/ml of (32P)-orthophosphate
and cells were further incubated for 2 hours at 37°C.
Where indicated, 1 μM okadaic acid (Sigma) was added to
block cellular PPP-phosphatases. Cells were washed with
PBS and lysed in whole cell lysis buffer (50 mM Tris-HCl,
pH 7.5, 0.5 M NaCl, 1% NP-40, 0.1% SDS) supplemented
with protease cocktail (Sigma). After 10 min on ice, cellu-
lar material was scraped and then centrifuged at 14,000
rpm, 4°C for 30 min. The supernatant was recovered and
immediately used for immunoprecipitation. Tat was pre-
cipitated with anti-Flag monoclonal antibodies coupled
to protein G agarose and with polyclonal anti-Tat anti-
bodies coupled to protein A agarose for 2 h at 4°C in a
TNN Buffer containing 50 mM Tris-HCl, pH 7.5, 0.15 M
NaCl, and 1% NP-40. The immunoprecipitated Tat was
recovered by heating for 2 min at 100°C in Tricine SDS-
loading buffer, resolved on 15% Tris-Tricine SDS-PAGE
[32] and transferred to polyvinylidene fluoride (PVDF)
membranes (Millipore, Allen, TX). The membrane was
analyzed with anti-Tat monoclonal antibodies using 3,3'-
Diaminobenzidine enhancer system (Sigma) and was also
exposed to Phosphor Imager screen (Packard Instruments,
Wellesley, MA).
Phosphoamino acid analysis
The analysis was carried out on the Hunter thin layer pep-
tide mapping electrophoresis system (CBS, Del Mar, CA)
according to the manufacturer's recommendations.
Briefly, phosphorylated Tat, prepared as described above
was resolved on 15% SDS-Tris-Tricine PAGE and the gel
was dried on a Whatman paper. The portion of the gel
containing Tat was excised, rehydrated and treated over-
night with trypsin to elute Tat. The eluted peptides were
boiled in 5.7 M HCl at 110°C to liberate (32P)-labeled
phospho-amino acids as described [57]. After the hydrol-
ysis, the sample was lyophilized and resuspended in the
buffer for pH 1.9 electrophoresis also containing the
phosphoamino acid standards at 0.06 mg/ml. The sample
was resolved by thin-layer electrophoresis on a cellulose
plate (CBS, Del Mar, CA) at pH 1.9 in the first direction
and at pH 3.5 in the second direction. Cold standards
were visualized by staining the plate with 0.25% ninhy-
drine dissolved in ethanol. Positions of labeled phos-
phoamino acids were analyzed with Phosphor Imager
(Packard Instruments, Wellesley, MA).
Transfection and HIV-1 detection from HLM1 cells
HLM-1cells were derived from HeLa-T4+ cells integrated
with one copy of HIV-1 genome containing a Tat-defective
mutation. The mutation was introduced as a triple termi-
nation linker (TTL) at the first AUG of Tat gene [54]. HLM-
1 cells are negative for virus particle production HLM1
cells are negative for virus particle production. HLM1 cells
can be induced to express non-infectious HIV-1 particles
after transfection with Tat cDNA, or by treatment with
mitogens such as TNF-α or sodium butyrate. HLM1 cells
were grown in DMEM media containing 100 μg/ml of
G418, plus 1% streptomycin, penicillin antibiotics and
1% L-Glutamine (Gibco/BRL). The cells grown up to 75%
confluence were transfected with Tat expression vectors,
including wild type Tat, S16A, S46A, and S16A/S46A
mutant Tat plasmids using the calcium phosphate
method. The transfected cells were washed after four hrs
and fresh complete DMEM media with 10% fetal bovine
was added for the remainder of the experiment. The p24
gag antigen was detected in the supernatants of trans-
fected cells using a standard ELISA kit (Abbott).
siRNA treatment
CDK2-directed siRNA pool (M-003236-03-005) and neg-
ative control pool (D-001206-13-05) were purchased
from Dharmacon (Dallas, TX). The siRNAs were trans-
fected at final concentration of 100 nM using Lipo-
fectamin reagent (Invitrogen) according to the
manufacturer's recommendations. The siRNAs were incu-
bated with cells for 2 days before cells were labeled with
32P or lysed for Western blotting analysis.
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